Response to methotrexate in a chronic inflammatory demyelinating polyradiculoneuropathy patient

Jordi Díaz-Manera, Ricard Rojas-García, Eduard Gallardo, Isabel Illa

Research output: Contribution to journalArticleResearchpeer-review

10 Citations (Scopus)

Abstract

We report a patient with chronic inflammatory demyelinating polyradiculoneuropathy and progressive resistance to standard treatment who showed a striking response to methotrexate, 20 mg/week. The improvement, which started 5 months after initiation of therapy, was consistent and permanent. It allowed the previously wheelchair-dependent patient to achieve pharmacological remission. The 2-year follow-up of this case further illustrates the role that methotrexate may play as a treatment option for CIDP patients. © 2009 Wiley Periodicals, Inc.
Original languageEnglish
Pages (from-to)386-388
JournalMuscle and Nerve
Volume39
Issue number3
DOIs
Publication statusPublished - 1 Mar 2009

Keywords

  • Chronic inflammatory demyelinating polyradiculoneuropathy
  • Intravenous inmunoglobulins
  • Methotrexate
  • Steroids
  • Treatment

Fingerprint

Dive into the research topics of 'Response to methotrexate in a chronic inflammatory demyelinating polyradiculoneuropathy patient'. Together they form a unique fingerprint.

Cite this